PCSK9 and atherosclerosis: PCSK9 mAbs, in combination with statins and/or ezetimibe, effectively decrease LDL-C by up to 50–60% and have now been shown to decrease the risk of ASCVD events proportional to the absolute reduction in LDL-C in two large-scale outcomes trials [3, 10, 11].